久久不见久久见毛片,2区在线视频,欧美另类区

WuXi AppTec's 2024 Financial report Financial statements WuXi AppTec's 2024 report reveals a 47% year-on-year increase in orders, with revenue at RMB 39.24 billion. The company expects growth in 2025, alongside special dividends and an A-share buyback plan.
Bayer's 2024 Financial report Financial statements Bayer's 2024 financial report reveals a 2.2% revenue decline, 6,908 job cuts, and ongoing legal battles. With strategic shifts and heavy R&D investment, the company faces challenges and opportunities ahead. Can Bayer turn the tide by 2025?
Legend Biotech 2024 Financial Performance Financial statements Legend Biotech reports 2024 revenue of $963M for CARVYKTI?. Over 5,000 patients treated, with expanded manufacturing and reimbursement approvals. Positive Phase 3 data shows high MRD negativity rates in multiple myeloma patients. Strong financial outlook for 2026.
Top 10 Global Paint Brands 2024 Market Trend Sherwin-Williams remains the world's top paint brand, with Nippon Paint closing in on AkzoNobel. Discover the 2024 financial performance of the top 10 global paint companies, including PPG, RPM, Axalta, BASF, Asian Paints, Kansai Paint, and Jotun.
2024 Perfume and Fragrance Industry Growth Financial statements In 2024, the four major fragrance and flavor giants (Symrise, DSM-Firmenich, IFF, Givaudan) report strong growth. Learn about their sales, profit drivers, and strategic plans for 2025 amidst global challenges.
DAI NIPPON's Tender Offer to Acquire Shinto: Low Price and Strategic Synergies Financial statements Deinte announces a tender offer to acquire Shindou Coatings at a 36% discount. The strategic acquisition aims to increase sales, enhance production efficiency, and expand Deinte's coatings business in a mature market.
Huntsman's 2024 Financial Report Financial statements Huntsman Corporation announces layoffs and reports Q4 2024 financial results, highlighting challenges in core markets like construction and automotive. The company also raises prices in response to cost pressures.
Ionis Pharmaceuticals 2024 Performance Report Financial statements Ionis Pharmaceuticals reported a 2024 revenue decline of 11%, with a $475 million operating loss. The report highlights product sales from Spinraza, Wainua, Qalsody, and others, alongside its cash reserves and 2025 guidance.
DSM-Firmenich's 2024 Financial Report DSM-Firmenich DSM-Firmenich's 2024 financial report shows strong growth, with sales reaching €12.8 billion and adjusted EBITDA up 19%. The company achieved higher profitability through restructuring, cost control, and innovation. Looking ahead, it targets €2.4 billion EBITDA in 2025.
Medpace's 2024 Financial Report Medpace Medpace’s 2024 financial report shows impressive growth, with a 50% surge in Q4 net profit and a 43% annual increase. The company forecasts 2025 revenue between $2.11B and $2.21B, continuing strong performance in the global CRO industry.

< Pre 1...6 7 8910 11 12...15 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水